CagriSema vs Semaglutide
Cagrilintide and semaglutide together in one weekly injection. In the phase 3 REDEFINE 1 trial, people lost 20.4% of body weight over 68 weeks against 3.0% on placebo — 22.7% among those who stayed on treatment [1]. Submitted to the US FDA in December 2025; not approved anywhere yet [9].
The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
CagriSema
0.25–2.4 mg
Semaglutide
0.5–1 mg
Frequency
CagriSema
Once weekly
Semaglutide
Once weekly
Administration
CagriSema
Subcutaneous injection
Semaglutide
Subcutaneous injection
Cycle length
CagriSema
Ongoing — 68-week phase 3 trials, with a 52-week maintenance period after escalation
Semaglutide
Ongoing/indefinite
Onset speed
CagriSema
Gradual — the full dose is only reached at week 16
Semaglutide
Moderate (1-2 weeks)
Evidence level
CagriSema
Strong human trials (Phase 3 or FDA approved)
Semaglutide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Weight Management
Blood Sugar Control
Appetite Control
Cardiometabolic Risk Factors
Weight Loss
Heart Protection
Compound specifications
CagriSema
Molecular formula
Cagrilintide C194H312N54O59S2 · Semaglutide C187H291N45O59
Molecular weight
Two peptides in one pen: ~4409 Da (cagrilintide) + ~4114 Da (semaglutide)
Half-life
Measured together: cagrilintide 159-195 hours, semaglutide 145-165 hours
CAS number
1415456-99-3 (cagrilintide) · 910463-68-2 (semaglutide)
Semaglutide
Molecular formula
C187H291N45O59
Molecular weight
4113.58 g/mol
Half-life
Approximately 7 days (168 hours)
Bioavailability
89% (subcutaneous); 0.4-1% (oral, with absorption enhancer)
CAS number
910463-68-2
Dosing compared
CagriSema
Subcutaneous
Weeks 1-4
0.25 mg each
Once weekly · Weeks 1-4 — escalation step 1
Both phase 3 REDEFINE trials initiated the fixed-dose pen at 0.25 mg of each drug [1]. Escalation step 1 in the trial protocol, held 4 weeks [7]. Human trials; 2,108 participants took the combination in REDEFINE 1 alone [1].
Weeks 5-8
0.5 mg each
Once weekly · Weeks 5-8 — escalation step 2
Escalation step 2 in the trial protocol, held 4 weeks [7]. The same participants stepped up from 0.25 mg — this is a true titration ladder, confirmed from the protocol and trial methods [1][7].
Weeks 9-12
1.0 mg each
Once weekly · Weeks 9-12 — escalation step 3
Escalation step 3 in the trial protocol, held 4 weeks [7]. Also studied as a maintenance dose in its own right: REIMAGINE 2 carried a cagrilintide-semaglutide 1.0 mg each arm of 595 people with type 2 diabetes for 68 weeks [5].
Weeks 13-16
1.7 mg each
Once weekly · Weeks 13-16 — escalation step 4
Escalation step 4 in the trial protocol, held 4 weeks before the maintenance dose [7].
Week 17
2.4 mg each
Once weekly · Week 17 on — maintenance (52 weeks in phase 3)
The maintenance dose in every phase 3 trial: 2.4 mg of each drug from week 16, held through a 52-week maintenance period in REDEFINE 1 [1]. Investigators could delay escalation or reduce the dose, and participants could stay on a submaximum dose — at week 68, 57.4% of the combination group was on the maximum dose, against 70.9% on semaglutide alone, 82.5% on cagrilintide alone and 70.6% on placebo [1]. Missed doses restarted one step lower per the protocol rules [7].
Semaglutide
Subcutaneous
4 weeks
0.25 mg
Once weekly · 4 weeks
This is the starter dose to help your body adjust. It does not lower blood sugar much on its own, so it is only used for the first 4 weeks before stepping up [5].
At least 4 weeks at each step
0.5-1 mg
Once weekly · At least 4 weeks at each step
After the starter month, the dose goes up to 0.5 mg, and can rise to 1 mg if more blood sugar control is needed. Wait at least 4 weeks before each increase [5].
Ongoing/maintenance
2-2.4 mg
Once weekly · Ongoing/maintenance
The highest weekly doses. 2 mg is the maximum for diabetes (Ozempic) [5]; up to 2.4 mg is used for weight management (Wegovy) after a slower titration.
Oral
30 days
3 mg
Once daily · 30 days
The pill form (Rybelsus) starts at 3 mg each morning for 30 days. Like the starter shot, this dose is for getting started and does not control blood sugar by itself. Take on an empty stomach with a small sip of water, 30 minutes before food or other pills [6].
30+ days
7 mg
Once daily · 30+ days
After the first 30 days, the dose increases to 7 mg once daily. This is the first dose that actively lowers blood sugar [6].
Ongoing/maintenance
14 mg
Once daily · Ongoing/maintenance
The highest pill dose, used if more blood sugar control is needed after at least 30 days at 7 mg [6].
Best suited for
CagriSema
Weight management
About 1 in 5 pounds of body weight lost (20.4%) over 68 weeks against 3.0% on placebo, and 22.7% among people treated as intended — shown in 3,417 adults without diabetes [1].
Type 2 diabetes with excess weight
13.7% weight loss against 3.4% on placebo at 68 weeks, and about 3 in 4 people (73.5%) reached an HbA1c of 6.5% or less against 15.9% on placebo — shown in 1,206 adults [2].
When semaglutide alone is not enough
Head-to-head at the same dose, the combination lost 5.5 percentage points more weight than semaglutide alone and 8.9 more than cagrilintide alone [1]; in 2,713 people with type 2 diabetes it also beat semaglutide 2.4 mg on HbA1c [5].
Semaglutide
People with Obesity Seeking Significant Weight Loss
If your BMI is 30 or higher (or 27+ with weight-related health conditions), semaglutide is currently one of the most effective non-surgical weight loss options available. [7] Clinical trials show average weight loss of 15% of body weight—that's 30+ pounds for someone starting at 200 pounds [1].
Those Who've Struggled with Diet and Exercise Alone
Semaglutide works by changing the biological signals that drive hunger and cravings. If you've tried to lose weight through willpower alone and found yourself constantly battling hunger, this medication addresses that underlying biology rather than just telling you to eat less [3][7][13].
People with Type 2 Diabetes Needing Better Control
Originally developed for diabetes, semaglutide excellently controls blood sugar while also promoting weight loss—addressing two major health concerns simultaneously. [3][5] It can often allow people to reduce or eliminate other diabetes medications [21].
Individuals at High Cardiovascular Risk
The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and existing heart disease—even without diabetes. It's one of the few weight loss medications proven to improve hard cardiovascular outcomes [2].
Side effects
CagriSema
Common
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Injection site reactions
Uncommon
- Fatigue and dizziness
- Hair loss (alopecia)
- Gallbladder-related disorders
Serious
- Serious adverse events
- Suspected acute pancreatitis
- Hypoglycaemia with insulin or sulfonylureas
Semaglutide
Common
- Nausea
- Constipation or Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Loss (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Safety & evidence
CagriSema
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Not approved anywhere. Submitted to the US FDA for weight management in December 2025 on the REDEFINE 1 and 2 trials; the type 2 diabetes pathway is still being discussed with regulators.
Safety overview
The safety picture comes from randomised trials with over 4,000 participants exposed to the combination [1][2][3][5]. In REDEFINE 1 (3,417 adults without diabetes), about 4 in 5 people on CagriSema (79.6%) had gastrointestinal events — nausea, vomiting, diarrhoea, constipation or abdominal pain — against about 2 in 5 on placebo (39.9%); most were transient and mild to moderate, peaked during dose escalation, and eased once escalation ended [1]. Any adverse event: 92.3% vs 82.3% on placebo; serious adverse events: about 1 in 10 (9.8%) vs 6.1% on placebo, most commonly hepatobiliary and gastrointestinal disorders; discontinuation of an active drug for adverse events: 5.9% vs 3.5% [1]. Two deaths occurred among the 2,108 people in the combination group; the adjudicated causes were suicide and cancer, and mental-health scores (C-SSRS, PHQ-9) were similar across all four groups throughout the trial [1]. In type 2 diabetes the pattern held: gastrointestinal events 72.5% vs 34.4% on placebo (REDEFINE 2, 1,206 adults) [2]; adverse events 86.9% on the full dose vs 81.2% on semaglutide 2.4 mg alone and 70.5% on placebo (REIMAGINE 2, 2,713 adults) [5]. Heart rate rose slightly (+0.94 beats per minute at week 68, vs +1.17 on semaglutide, -3.31 on cagrilintide and -0.58 on placebo) [1]. In the 32-week phase 2 diabetes trial no level 2 or 3 hypoglycaemia and no fatal events were reported [3].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 — boxed-warning contraindication for the semaglutide component [7][8]
- Prior serious hypersensitivity to semaglutide, cagrilintide, or their excipients [7][8]
- Pregnancy — trials discontinued treatment on pregnancy [7]
- Not approved anywhere — investigational combination [9]
Semaglutide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Semaglutide has been studied in over 20,000 participants across multiple large clinical trials, making it one of the most thoroughly researched weight loss medications available. [1][2][8][9][10] The FDA approved it after rigorous review of safety data. While GI side effects are common (especially early on), serious side effects are rare. [1][7] The SELECT trial showed it actually reduces cardiovascular events, adding a safety benefit beyond just weight loss [2].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) [7]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [7]
- History of serious allergic reaction to semaglutide [7]
Which is right for you?
Choose CagriSema if...
- Weight loss
- Blood sugar control
- Appetite control
- Metabolic health
Choose Semaglutide if...
- Significant weight loss
- Long-term weight management
- Cardiovascular risk reduction
- Blood sugar control